S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
The gold catalyst we’ve waited for (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
The gold catalyst we’ve waited for (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
The gold catalyst we’ve waited for (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Scottish independence at crossroads in testy SNP leader race
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
The gold catalyst we’ve waited for (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
The gold catalyst we’ve waited for (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
The gold catalyst we’ve waited for (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Scottish independence at crossroads in testy SNP leader race
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
The gold catalyst we’ve waited for (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
The gold catalyst we’ve waited for (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
The gold catalyst we’ve waited for (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Scottish independence at crossroads in testy SNP leader race
S&P 500   3,916.64
DOW   31,861.98
QQQ   305.36
Risk-Free Money Market vs. Bank Dividend Stock, Which is Better?
The gold catalyst we’ve waited for (Ad)
Deal for UBS to buy Credit Suisse sends shares tumbling
Gunmen kill 9 Chinese at mine in Central African Republic
The gold catalyst we’ve waited for (Ad)
Niinistö: Sweden security OK if Finland joins NATO first
The End of Coca Cola's Compressed Margins
The gold catalyst we’ve waited for (Ad)
Which Gold Stocks Can Help You Hedge Bank Exposure?
Scottish independence at crossroads in testy SNP leader race
NASDAQ:AADI

Aadi Bioscience - AADI Stock Forecast, Price & News

$7.52
-0.24 (-3.09%)
(As of 03/17/2023 08:53 PM ET)
Add
Compare
Today's Range
$7.40
$8.03
50-Day Range
$7.40
$13.00
52-Week Range
$7.00
$20.09
Volume
192,800 shs
Average Volume
127,975 shs
Market Capitalization
$183.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.67

Aadi Bioscience MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
454.1% Upside
$41.67 Price Target
Short Interest
Bearish
7.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.05mentions of Aadi Bioscience in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.70) to ($2.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

650th out of 983 stocks

Pharmaceutical Preparations Industry

310th out of 480 stocks


AADI stock logo

About Aadi Bioscience (NASDAQ:AADI) Stock

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.

Receive AADI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter.

AADI Stock News Headlines

Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Aadi Bioscience Announces Leadership Transition
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
Aadi Bioscience Third Quarter 2022 Earnings: Beats Expectations
Aadi Bioscience Announces Planned Leadership Transition
See More Headlines
Receive AADI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter.

AADI Company Calendar

Last Earnings
8/10/2021
Today
3/20/2023
Next Earnings (Confirmed)
3/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AADI
Fax
N/A
Employees
39
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.67
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+454.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-110,090,000.00
Net Margins
-569.57%
Pretax Margin
-569.49%

Debt

Sales & Book Value

Annual Sales
$1.12 million
Cash Flow
$1.77 per share
Book Value
$6.53 per share

Miscellaneous

Free Float
16,637,000
Market Cap
$183.49 million
Optionable
Not Optionable
Beta
1.25

Key Executives

  • Brendan Delaney
    President & Chief Executive Officer
  • Scott M. Giacobello
    Treasurer, Chief Financial & Accounting Officer
  • Berta Grigorian
    Vice President-Clinical Operations
  • Loretta M. Itri
    Chief Medical Officer
  • Andrew Kwon
    Senior Director-Business Development & Strategy













AADI Stock - Frequently Asked Questions

Should I buy or sell Aadi Bioscience stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aadi Bioscience in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AADI shares.
View AADI analyst ratings
or view top-rated stocks.

What is Aadi Bioscience's stock price forecast for 2023?

1 analysts have issued 1 year price targets for Aadi Bioscience's stock. Their AADI share price forecasts range from $30.00 to $48.00. On average, they anticipate the company's stock price to reach $41.67 in the next twelve months. This suggests a possible upside of 454.1% from the stock's current price.
View analysts price targets for AADI
or view top-rated stocks among Wall Street analysts.

How have AADI shares performed in 2023?

Aadi Bioscience's stock was trading at $12.83 on January 1st, 2023. Since then, AADI shares have decreased by 41.4% and is now trading at $7.52.
View the best growth stocks for 2023 here
.

Are investors shorting Aadi Bioscience?

Aadi Bioscience saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 1,180,000 shares, an increase of 6.3% from the February 13th total of 1,110,000 shares. Based on an average daily trading volume, of 104,500 shares, the short-interest ratio is currently 11.3 days. Approximately 7.3% of the company's shares are short sold.
View Aadi Bioscience's Short Interest
.

When is Aadi Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our AADI earnings forecast
.

How can I listen to Aadi Bioscience's earnings call?

Aadi Bioscience will be holding an earnings conference call on Tuesday, March 28th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Aadi Bioscience's earnings last quarter?

Aadi Bioscience, Inc. (NASDAQ:AADI) announced its quarterly earnings results on Tuesday, August, 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.00) by $2.33. Aadi Bioscience had a negative trailing twelve-month return on equity of 44.28% and a negative net margin of 569.57%.

What ETF holds Aadi Bioscience's stock ?

ALPS Medical Breakthroughs ETF holds 16,567 shares of AADI stock, representing 0.13% of its portfolio.

When did Aadi Bioscience's stock split?

Aadi Bioscience shares reverse split on the morning of Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Aadi Bioscience's stock symbol?

Aadi Bioscience trades on the NASDAQ under the ticker symbol "AADI."

Who are Aadi Bioscience's major shareholders?

Aadi Bioscience's stock is owned by a number of retail and institutional investors. Top institutional investors include Alerce Investment Management L.P. (6.68%), Geode Capital Management LLC (1.07%), Opaleye Management Inc. (1.03%), Renaissance Technologies LLC (1.03%), Price T Rowe Associates Inc. MD (1.01%) and ExodusPoint Capital Management LP (0.31%). Insiders that own company stock include Caley Castelein, Neil Desai and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of Aadi Bioscience?

Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aadi Bioscience's stock price today?

One share of AADI stock can currently be purchased for approximately $7.52.

How much money does Aadi Bioscience make?

Aadi Bioscience (NASDAQ:AADI) has a market capitalization of $183.49 million and generates $1.12 million in revenue each year. The company earns $-110,090,000.00 in net income (profit) each year or ($2.98) on an earnings per share basis.

How can I contact Aadi Bioscience?

Aadi Bioscience's mailing address is 9987 Carver Rd, Blue Ash, Ohio 45242-5550. The official website for the company is aadibio.com. The company can be reached via phone at (424) 473-8055 or via email at ikoffler@lifesciadvisors.com.

This page (NASDAQ:AADI) was last updated on 3/20/2023 by MarketBeat.com Staff